Business Wire

BLS International Holding Anonim Şirketi (Turkey) Successfully Completes Acquisition of 100% Stake in iDATA

12.7.2024 15:32:00 EEST | Business Wire | Press release

Share

BLS International Services Limited, a leading global tech-enabled service partner for governments and citizens, announced the successful completion of the acquisition of 100% stake in iDATA and its wholly owned subsidiaries, through BLS International FZE (WoS of BLS) and BLS International Holding Anonim Şirketi (WoS of BLS International FZE).

Turkey-based iDATA, a leading visa service provider with 37+ VACs in 15+ countries, serves Germany, Italy, and the Czech Republic. BLS acquired iDATA for ~Euro 80 Million. In 2023, iDATA reported revenues of ~Euro 27.3 Million and EBITDA of ~Euro 16 Million.

This acquisition would further strengthen the overall BLS’ position as one of the leading international player in Visa and Consular services. iDATA’s existing agreements and offices will be aligned into the BLS’s network in 66 countries across the globe, enabling BLS to service more Client Governments in Europe. The transaction will be EPS (Earning per share) accretive to BLS immediately.

Mr. Shikhar Aggarwal, Joint Managing Director of BLS International said: “We are delighted to announce the completion of the iDATA acquisition, a pivotal point in BLS’ growth journey and a testament to our strategic vision of leading global visa and consular services. iDATA, with 15 years of specialized experience, has built strong relationships with client governments. This acquisition enables BLS to expand relationships in Europe, enhance visibility, and consolidate market share. We expect positive financial impacts and improved margins from combined synergies. We thank both teams for addressing regulatory requirements and welcome iDATA employees to new opportunities.”

About BLS International:

BLS International Services Ltd., established in 2005, is a global leader in visa, passport, consular, and citizen services, recognized as one of the top 2 firms in its field with over 19 years of experience. It boasts collaborations with over 46 client governments and operates across 66 countries. The company is acclaimed for its data security and service quality, processing over 360 million applications to date. It has received numerous accolades from prestigious publications and holds several quality and security certifications. Uniquely, BLS International is the only publicly traded entity in its sector, listed on BSE, NSE, and MSE, underscoring its industry prominence and commitment to excellence.

For more information, please visit www.blsinternational.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240711577375/en/

Contacts

BLS International Services Limited
Pallavi Mohan
Global Head - Corporate Communications
pallavi.mohan@blsinternational.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

EADV 2026: Galderma to Unveil New Data Advancing Understanding of Skin Diseases, Skin Longevity, and Real-world Patient Experiences23.9.2026 08:00:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, will present 19 abstracts and deliver a broad scientific education program at the 2026 European Academy of Dermatology and Venereology (EADV) Congress. Through these activities, Galderma will showcase how it continues to advance its pipeline and the science of dermatology, deepening understanding of biological and quality-of-life factors, while driving innovation in targeted treatments, skin longevity and evidence-based care. “At Galderma, we recognize that advancing dermatology means not only addressing the needs of patients living with common chronic skin conditions, such as atopic dermatitis and acne, but also anticipating the trends that will shape the future of skin health. Our presence at EADV demonstrates our unique ability to achieve this, with new data spanning both established areas of unmet need and emerging fields such as skin longevity, helping drive innovation and meaningful outcomes for patients today and i

Oticon Medical Launches SmartCharger for the Ponto 5 Family23.9.2026 08:00:00 EEST | Press release

Oticon Medical today announces the launch of SmartCharger for the Ponto 5 family, introducing its first rechargeable solution for percutaneous sound processors and marking a new step in convenience and portability for bone anchored hearing system users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922863462/en/ Oticon Medical today announces the launch of SmartCharger for the Ponto 5 family, introducing its first rechargeable solution for percutaneous sound processors and marking a new step in convenience and portability for bone anchored hearing system users. Powering the Ponto 5 family The launch of SmartCharger underlines Oticon Medical’s continued commitment to the Ponto family, which includes Ponto 5 SuperPower, the world’s most powerful abutment-level sound processor,1 and Ponto 5 Mini, the world’s smallest percutaneous sound processor.1 By bringing rechargeable convenience to the Ponto sound processors, Oticon Me

Textron Aviation Marks 500th Cessna Citation Latitude Rollout22.9.2026 17:19:00 EEST | Press release

Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, today announced the rollout of the 500th Cessna Citation Latitude business jet from the company’s Wichita, Kansas, manufacturing facility. The production milestone highlights the continued success of the world’s best-selling midsize business jet and recognizes the employees whose craftsmanship and dedication have helped make the Citation Latitude the trusted choice for operators around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922867287/en/ Textron Aviation marks 500th Cessna Citation Latitude rollout. (Photo Credit: Textron Aviation) “The rollout of the 500th Citation Latitude is a testament to the employees who build this aircraft with dedication and pride every day,” said Eric Cardinali, senior vice president, Manufacturing. “Behind every aircraft is a team committed to delivering the quality and craftsmanship our customers expect. This milestone

OCP Announces Date of Second Quarter and First Half 2026 Earnings22.9.2026 17:00:00 EEST | Press release

OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its second quarter and first half 2026 results on Tuesday, September 29, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 10:00 a.m. EDT, 2:00 p.m. Morocco (GMT) and 3:00 p.m. London time (GMT+1). OCP senior management will host a conference call to discuss second quarter and first half 2026 results at 11:00 a.m. EDT, 3:00 p.m. Morocco (GMT) and 4:00 p.m. London time (GMT+1) on Tuesday, September 29, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century

Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 202622.9.2026 16:30:00 EEST | Press release

Takeda(TSE:4502/NYSE:TAK)announced that new data from its oncology pipeline and portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026, in Madrid, Spain. Key data will include a late-breaking abstract on arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343*) and two presentations on TAK-928 (Innovent R&D code: IBI363*). Clinical and real-world analyses of ALUNBRIG® (brigatinib) and FRUZAQLA® (fruquintinib) will also be shared at the congress. “Takeda’s data at ESMO reflect our commitment to delivering rapid progress for patients living with some of the most prevalent and challenging cancers, including advanced gastric cancer and immunotherapy-resistant and previously untreated non-small cell lung cancer,” said Phuong Khanh (P.K.) Morrow, M.D., Head of the Oncology Therapeutic Area Unit at Takeda. “Our mission is to advance new therapeutic approaches for patients who need more options or who remain underserved by cur

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye